Journal of Pharmaceutical and Biomedical Sciences

Login
Select Language
Subscription Login to verify subscription
Give a gift subscription
Article Tools
Print this article
Indexing metadata
How to cite item
Finding References
Review policy
Email this article (Login required)
Email the author(Login required)
Post a Comment (Login required)

Mechanism of Inflammatory Pain and Implementation of Natural Products as Rescue Route

David Adeiza Otohinoyi, Olugbenga Morebise, Adegbenro O motuyi, John Fakoya

Abstract


The onset of pain is the major discomfort associated with inflammation. The inflammation is usually associated with tissue injury, irritation and infection. This leads to the release of pro-inflammatory compounds from either damaged or immune cells leading to the stimulation of nociceptors which are mainly primary afferent fibres. The stimulation of these fibres by neuropeptide, substance P, prostaglandins, leukotrienes, histamine, serotonin, protons and others leads to pain. To ease this pain, the drugs tend to either inhibit the enzymes or the nerve receptors. The major means of controlling the pain involves the inhibition of cyclooxygenase and lipoxygenase pathways. However, the effective inhibition of these enzymes tends also to impede other functional physiological activities occurring in the body, leading to health crisis. The steps in eradicating these lethal side effects have led to the various techniques including natural remedies like plants and fish oils. Therefore, this study tends to present a review on the pain sensation pathway during inflammation and how the introduction of natural products in drug therapies could prove lucrative.

Keywords


inflammation, irritation, infection, pain sensation

Full Text:

References


Visha MG. Selective Cox-2 inhibitor. Int J Pharm Sci Interv. 2013;3(2):28–33.

Ferreira SH. Inflammatory pain: the role of cytokines and its control by drugs which release nitric oxide. Ann Ist Super Sanita.1993;29(3):367–373.

Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–84.

Percival M. Understanding the natural management of pain and inflammation. Clin Nutr Insight.1997;30:1–5.

Zarghi A, Zebardast T, Daraie B, Hedayati M. Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem.2009;17:5369–5373.

Zarghi A, Arefi H, Dadrass OG, Torabi S. Design and synthesis of new 2-aryl, 3-benzyl-(1,3-oxazolidine or 1,3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors. Med Chem Res. 2010;19:782–793.

Zarghi A, Arfaei S. Selective Cox-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011;10(4): 655–683.

Patel NB. Physiology of pain. 2010. Accessed from: https://www. uonbi.ac.ke/npatel/files/chapter_3_physiology_of_pain_.pdf

Marchand S. The physiology of pain mechanisms: from the periphery to the brain. Rheum Dis Clin North Am. 2008;34:285–309.

Fein A. Nociceptors and the perception of pain. 2012. Accessed from: http://cell.uchc.edu/pdf/fein/nociceptors_fein_2012.pdf

Jaggar SI. Overview of pain pathways. In: Holdcroft A, Jaggar S (eds): Core topics in pain. New York: Cambridge University Press;2005. pp. 3–5.

Melzack R, Wall PD. Pain mechanisms: a new theory. Science.1965;150:971–979.

Cafferty W. Peripheral mechanisms. In: Holdcroft A, Jaggar S (eds): Core topics in pain. New York: Cambridge University Press;2005. pp. 8–15.

Echeverry S, Lee SH, Lim T, Zhang J. Contribution of inflammation to chronic pain triggered by nerve injury. 2012. Accessed from: http://cdn.intechopen.com/pdfs-wm/34132.pdf

Ferreira SH, Nakamura M. I-prostaglandin hyperalgesia: a cAMP/ Ca++ dependent process. Prostaglandins. 1979;18:179–190.

Finnerup NB, Jensen TS. Nerve damage and its relationship to neuropathic pain. In: Holdcroft A, Jaggar S (eds): Core topics in pain. New York: Cambridge University Press; 2005. pp. 43–47.

Farquhar-Smith WP, Kerr BJ. Inflammation and pain. In: Holdcroft A, Jaggar S (eds): Core topics in pain. New York: Cambridge University Press; 2005. pp. 37–41.

DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001;90:1–6.

Boddeke EW. Involvement of chemokines in pain. Eur J Pharmacol. 2001;429:115–119.

Burnstock G. P2X receptors in sensory neurones. Br J Anaesth. 2000;84:476–488.

Waldron JB, Sawynok J. Peripheral P2X receptors and nociception: interactions with biogenic amine systems. Pain. 2004;110:79–89.

Hawkins PT, Stephens LR. PI3K signaling in inflammation. Biochim Biophys Acta. 2015;185:1882–1889.

Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–435.

Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159–175.

Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated.Nat Rev Immunol. 2007;7:678–689.

Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med. 2002;8:390–396.

Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase: a new avenue in anti-inflammatory therapy. Biochem Pharmacol. 2001;62:1433–1438.

Claria J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9: 2177–2190.

Uddin MJ, Rao PNP, McDonald R, Knaus EE. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase- 2 (COX-2) isozyme. Bioorg Med Chem Lett. 2005;15:439–442.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971;231:232–235.

Hata AN, Breyer RM. Pharmacology and signalling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;03:147–166.

Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem. 2003;38:645–659.

Dannhardt G, Kiefer W. Cyclooxygenase inhibitors current status and future prospects. Eur J Med Chem. 2001;36:109–126.

Brock TG. Regulating leukotriene synthesis: the role of nuclear 5-lipoxygenase. J Cell Biochem. 2005;96:1203–1211.

Wisastra R, Dekker FJ. Inflammation, cancer, oxidative lipoxygenase activity are intimately linked. Cancers. 2014;6:1500–1521.

Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010;177:1576–1591.

Noiri E, Yokomizo T, Nakao A, Izumi T, Fujita T, Kimura S et al. An in vivo approach showing the chemotactic activity of leukotriene B4 in acute renal ischemic-reperfusion injury. Proc Nat Acad Sci. 2000;18:823–828.

Nowsheen K, Aziz TB, Kryston NF, Ferguson NF, Georgakilas A. The interplay between inflammation and oxidative stress and carcinogenesis. Curr Mol Med. 2012;12:672–680.

Lawerance T. The nuclear factor NF-?B pathway in inflammation. CSH Perspect. Biol. 2009;1(6):a001651.

Govindappa M, Sadananda TS, Channabasava R, Raghavendra VB. In vitro anti-inflammatory, lipoxygenase, xanthine oxidase and acetycholinesterase inhibitory activity of Tecoma stans (l.) Juss. Ex kunth. Int J Pharm Biosci. 2011;2(2):275–285.

Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol. 2006;1:236–245.

Katori M, Majima M. Cyclooxygenase-2: its rich diversity roles and possible application of its selective inhibitors. Inflamm Res. 2000;49:367–392.

Kuhn H, O’Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res. 2006;45:334–356.

Alvero-Gracia JM. Licofelone-clinical update on a novel LOX/ COX inhibitor for the treatment osteoarthritis. Rheumatology.2004;43:i21–i25.

Chen QH, Rao PNP, Knaus EE. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs). Bioorg Med Chem Lett. 2006;14:7898–7909.

Ye W, Zhang H, Hillas E, Kohan DE, Miller RL, Nelson RD, et al. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol. 2006;290:F542–F549.

Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384: 644–648.

Lima GRM, Montenegro CA, Almeida CLF, Athayde-Filho PF, Barbosa-Filho JM, Batista LM. Database survey of anti-inflammatory plants in South America: a review. Int J Mol Sci. 2011;12:2692–2749.

Kumar S, Bajwa BS, Kuldeep S, Kalia AN. Anti-inflammatory activity of herbal plants: a review. Int J Adv Pharm Biol Chem. 2013;2(2):272–281.

Murugesan D, Deviponnuswamy R. Potential anti-inflammatory medicinal plants: a review. Int J Pharm Pharm Sci. 2014;6(4):43–49.

Chi Y, Jong H, Son K, Chang H, Kang S, Kim H. Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem Pharmacol. 2001;62:1185–1191.

Aganihotri S, Wakode S, Aganihotri A. An overview on anti-inflammatory properties and chemo-profiles of plants used in traditional medicine. Indian J Nat Prod Res. 2010;1(2):150–167.

Chrubasik S, Eisenberg E, Balan E, Weinberger T, Luzzati R, Conradt C. Treatment of low back pain exacerbations with willow bark extracts: a randomized double-blind study. Am J Med. 2000;109(1):9–14.

Cobiac L, Clifton PM, Abbey M, Belling GB, Nestel PJ. Lipid, lipoprotein, and hemostatic effects of fish vs. fish-oil n-3 fatty acids in mildly hyperlipidemic males. Am J Clin Nutr. 1991;53:1210–1216.

Olaleye SB, Oke JM, Etu AK, Omotosho IO, Elegbe RA. Antioxidant and anti-inflammatory properties of a flavonoid fraction from the leaves of voacanga Africana. Niger J Physiol Sci. 2004;19(1–2):69–76.

Hemamalini K, Naik KOM, Ashok P. Anti-inflammatory and analgesic effect of methanolic extract of Anogeissus acuminata leaf. Int J Pharm Biomed Res. 2010;1(3):98–101.

Vieira-de-Sousa O, Vieira GD, Jesus J, Pinho RG, Yamamoto CH, Alves MS. Antinociceptive and anti-inflammatory activities of the ethanol extract of Annonamuricata L. leaves in animal models. Int J Mol Sci. 2010;11(5):2067–2078.

Leboeuf M, Cavé A, Bhaumik PK, Mukherjee B, Mukherjee R. The phytochemistry of the annonaceae. Phytochemistry. 1982;21:2783–2813.

Kantamreddi VSSN, Lakshmi YN, Kasapu VVVS. Preliminary phytochemical analysis of some important Indian plant species. Int J Pharm Bio Sci. 2010;1(4):351–358.

Ayoola GA, Folawewo AD, Adesegun SA, Abioro OO, Adepoju- Bello AA, Coker HAB. Phytochemical and antioxidant screening of some plants of apocynaceae from South West Nigeria. African J Plant Sci. 2008;2(9):124–128.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.